The Latest News March 30, 2021 argenx announces Annual General Meeting of Shareholders on May 11, 2021 Breda, the Netherlands argenx SE today announced that an annual general meeting of shareholders will be held at 10:00 a.m. CEST on Tuesday May 11, 2021 at the Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands. Read argenx announces Annual General Meeting of Shareholders on May 11, 2021 More Press Releases News May 7, 2021 argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its... Read News April 28, 2021 argenx Management to Present at Upcoming Virtual Investor Conferences argenx today announced that members of management will participate in the following upcoming conferences: Read News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read Media center ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags April 7, 2020 SIMPLE Antibody platform / Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform April 7, 2020 SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics April 7, 2020 SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy April 7, 2020 Cusatuzumab / CD70: An emerging target in cancer immunotherapy April 7, 2020 Cusatuzumab / Phase 1 dose-escalation study of the anti-CD70 antibody ARGX-110 in Advanced Malignancies Load more
News May 7, 2021 argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its... Read
News April 28, 2021 argenx Management to Present at Upcoming Virtual Investor Conferences argenx today announced that members of management will participate in the following upcoming conferences: Read
News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read
